Abstract:Background: Propagation of neuronal α-synuclein aggregate pathology to the cortex and hippocampus correlates with cognitive impairment in Parkinson's disease (PD) dementia and dementia with Lewy body disease. Previously, we showed accumulation of the parkin substrate aminoacyl-tRNA synthetase interacting multifunctional protein-2 (AIMP2) in the temporal lobe of postmortem brains of patients with advanced PD. However, the potential pathological role of AIMP2 accumulation in the cognitive dysfunction of patients with PD remains unknown. Methods: We performed immunofluorescence imaging to examine cellular distribution and accumulation of AIMP2 in brains of conditional AIMP2 transgenic mice and postmortem PD patients. The pathological role of AIMP2 was investigated in the AIMP2 transgenic mice by assessing Nissl-stained neuron counting in the hippocampal area and Barnes maze to determine cognitive functions. Potential secretion and cellular uptake of AIMP2 was monitored by dot blot analysis and immunofluorescence. The utility of AIMP2 as a new PD biomarker was evaluated by dot blot and ELISA measurement of plasma AIMP2 collected from PD patients and healthy control followed by ROC curve analysis. Results: We demonstrated that AIMP2 is toxic to the dentate gyrus neurons of the hippocampus and that conditional AIMP2 transgenic mice develop progressive cognitive impairment. Moreover, we found that neuronal AIMP2 expression levels correlated with the brain endothelial expression of AIMP2 in both AIMP2 transgenic mice and in the postmortem brains of patients with PD. AIMP2, when accumulated, was released from the neuronal cell line SH-SY5Y cells. Secreted AIMP2 was taken up by human umbilical vein endothelial cells. Consistent with the fact that AIMP2 can be released into the extracellular space, we showed that AIMP2 transgenic mice have higher levels of plasma AIMP2. Finally, ELISA-based assessment of AIMP2 in plasma samples from patients with PD and controls, and subsequent ROC curve analysis proved that high plasma AIMP2 expression could serve as a reliable molecular biomarker for PD diagnosis. Conclusions: The pathological role in the hippocampus and the cell-to-cell transmissibility of AIMP2 provide new therapeutic avenues for PD treatment, and plasma AIMP2 combined with α-synuclein may improve the accuracy of PD diagnosis in the early stages.

Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; Therapeutic implication for Parkinson's disease

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s disease

Blocking the Self‐Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition

Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease

Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson's disease

Chemical induction of the interaction between AIMP2-DX2 and Siah1 to enhance ubiquitination

Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future

Inhibitor of apoptosis stimulating protein of p53 protects against MPP+-induced neurotoxicity of dopaminergic neurons

Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease

Inhibition of Protease-Activated Receptor-2 Activation in Parkinson's Disease Using 1-Piperidin Propionic Acid

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease

Data from Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2

The D2 Dopamine Receptor Interferes with the Protective Effect of the A(2A) Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration

Oncogenic Mutation of AIMP 2 / P 38 Inhibits Its Tumor-Suppressive Interaction with Smurf 2

MicroRNA-212-5p Prevents Dopaminergic Neuron Death by Inhibiting SIRT2 in MPTP-Induced Mouse Model of Parkinson’s Disease

Therapeutic potential of Parkin and its regulation in Parkinson's disease